Novo Nordisk News
Most Popular Novo Nordisk Story
FDA approves Novo's blockbuster diabetes drug
After an exhaustive 21-month review, the FDA has extended its approval for the blockbuster new type 2 diabetes drug Victoza (liraglutide). And the news quickly spurred shares of Novo Nordisk higher.... Read more...
Latest Headlines
- January 26, 2010
- December 31, 2009
- December 22, 2009
- December 8, 2009
- October 23, 2009
- September 23, 2009
- August 6, 2009
- June 8, 2009
- April 24, 2009
- April 3, 2009
- January 29, 2009
- January 23, 2009
- January 16, 2009
- December 17, 2008
- October 17, 2008
- September 28, 2008
- September 8, 2008
- August 6, 2008
- July 29, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
